All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

BI 764532 Shows Early Efficacy, Manageable Tolerability in DLL3+ SCLC and Neuroendocrine Carcinoma

June 4th 2023

When administered at doses of 90 μg/kg or higher, the novel DLL3-targeting T-cell engager, BI 764532, was found to have an acceptable toxicity profile and to elicit encouraging responses in patients with DLL3-positive small cell lung cancer and neuroendocrine carcinoma.

Talquetamab Plus Daratumumab Produces Potent Responses in R/R Multiple Myeloma

June 4th 2023

Talquetamab plus daratumumab displayed high response rates regardless of 0.4 mg/kg or 0.8 mg/kg dosing in combination with daratumumab in patients with heavily pretreated relapsed/refractory multiple myeloma, irrespective of prior treatment with CD38-directed therapy and T-cell redirection therapy.

Dostarlimab Plus Chemo Leads to PFS Improvement in dMMR/MSI-H Advanced Endometrial Cancer

June 4th 2023

The combination of dostarlimab with standard-of-care carboplatin and paclitaxel elicited a statistically significant and clinically meaningful improvement in progression-free survival vs carboplatin/paclitaxel plus placebo in patients with mismatch repair–deficient/microsatellite instability–high advanced or recurrent endometrial cancer.

Cabozantinib Plus Nivolumab and Ipilimumab Elicits Meaningful Activity in RCCvh

June 3rd 2023

Triplet therapy with cabozantinib, nivolumab, and ipilimumab demonstrated clinical meaningful activity in patients with renal cell carcinoma with variant histologies.

Anxiety/Depression Symptoms Improve in Patients With Cancer After Using Stress Management App

June 3rd 2023

Positive changes in symptoms of anxiety and depression were reported in patients with cancer following the use of a cognitive behavioral stress management app.

Linvoseltamab Shows High Response Rate, Manageable Toxicity for Pretreated Myeloma

June 3rd 2023

The BCMA/CD3 bispecific linvoseltamab elicited an objective response rate of 71% at the recommended dose of 200 mg for patients with relapsed/refractory multiple myeloma.

PHE855 Generates High Response and MRD Negativity Rates in Relapsed/Refractory Myeloma

June 3rd 2023

The CAR T-cell therapy PHE885 produced responses and high minimal residual disease negativity rates with no new safety signals in patients with relapsed/refractory multiple myeloma.

Teclistamab/Talquetamab Combo Shows Early Safety, Efficacy in R/R Multiple Myeloma

June 3rd 2023

Teclistamab-cqyv in combination with talquetamab showcased early signs of activity with acceptable safety in patients with relapsed/refractory multiple myeloma, according to final results from the phase 1b RedirecTT-1 study.

Efficacy of CLDN6-Directed CAR T Therapy Is Maintained With Automated Manufacturing in Solid Tumors

June 3rd 2023

When manufactured via automated process the CLDN6-directed CAR T-cell therapy, BNT211, demonstrated encouraging signs of activity and a manageable safety profile with or without the addition of CLDN6-encoding mRNA vaccine in patients with CLDN6-positive relapsed/refractory advanced solid tumors.

Subsequent Treatments Feasible After Radium-223 in mCRPC

June 3rd 2023

Radium-223 was safe and did not preclude patients with metastatic castration-resistant prostate cancer from receiving subsequent life-prolonging therapies, including chemotherapy.

Belzutifan/Lenvatinib Elicits Responses in Advanced ccRCC After Progression on ICI and VEGF TKI

June 3rd 2023

Belzutifan plus lenvatinib generated responses and displayed a manageable safety profile in patients with advanced clear cell renal cell carcinoma whose disease progressed following treatment with a PD-1/L1 inhibitor and a VEGF TKI.

Talazoparib Plus Enzalutamide Has Manageble Toxicity With Dose Modifications, Supportive Care in mCRPC

June 3rd 2023

The use of talazoparib plus enzalutamide was manageable with dose modifications or standard supportive care treatment in patients with metastatic castration-resistant prostate cancer.

Real-World Data Detail Potential Benefits of Darolutamide Over Other ARIs in nmCRPC

June 3rd 2023

Patients with nonmetastatic castration-resistant prostate cancer who received darolutamide were observed to have a longer time to treatment discontinuation and progression to metastatic castration-resistant disease than those who received enzalutamide or apalutamide.

Perioperative Pembrolizumab Shows Strong EFS, Response in Early-Stage NSCLC

June 3rd 2023

The addition of pembrolizumab to neoadjuvant platinum-based chemotherapy followed by resection and adjuvant pembrolizumab alone resulted in a significant improvement in event-free survival and pathological response for patients with early-stage non–small cell lung cancer.

Zanidatamab Elicits Responses in HER2-amplified Advanced Biliary Tract Cancer

June 3rd 2023

Zanidatamab generated responses in patients with HER2-amplified, locally advanced, unresectable or metastatic biliary tract cancer who were previously treated with gemcitabine.

NALIRIFOX Elicits Statistically Significant Improvement in OS/PFS in Previously Untreated mPDAC

June 3rd 2023

Liposomal irinotecan plus 5-fluorouracil/leucovorin and oxaliplatin generated statistically significant and clinically meaningful overall survival and progression-free survival benefits compared with gemcitabine plus nab-paclitaxel in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma.

HIMALAYA Safety Data Support STRIDE Regimen as A Global Treatment Option for uHCC

June 3rd 2023

Patients with unresectable hepatocellular carcinoma experienced manageable and low-grade immune-related adverse events with single tremelimumab regular interval durvalumab.

Addition of Up-front Durvalumab, Maintenance Olaparib to Standard Therapy Improves PFS in Advanced Ovarian Cancer

June 3rd 2023

The addition of durvalumab to standard upfront therapy with chemotherapy and bevacizumab followed by maintenance bevacizumab, durvalumab, and olaparib led to a statistically significant improvement in progression-free survival compared with chemotherapy and bevacizumab alone in patients with newly diagnosed, advanced ovarian cancer without a BRCA1/2 mutation.

Efficacy and Safety of Abemaciclib Plus ET Is Maintained Older Patients with HR+, HER2–, Early Breast Cancer

June 3rd 2023

A clinically meaningful absolute risk reduction in invasive disease-free survival and distant relapse-free survival with abemaciclib plus endocrine therapy was maintained in patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer regardless of age.

Retrospective Study Confirms Real-World Efficacy of Brexucabtagene Autoleucel in R/R B-ALL

June 2nd 2023

Brexucabtagene autoleucel elicited high rates of complete remission with minimal residual disease negativity in real-world patients with relapsed or refractory B-cell acute lymphoblastic leukemia who received the CAR T-cell product as post-approval, standard-of-care treatment, according to data from a retrospective study.